Nipro Vialex – 26th January 2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Nasal & Pulmonary Drug Development
Novo Nordisk 20 March 2024, 11:21
Carterra – 24th March 2025

FDA nod for Kiniksa’s Arcalyst in recurrent pericarditis

The US Food and Drug Administration (FDA) has approved Kiniksa Pharmaceuticals’ interleukin-1 alpha (IL-1?) and interleukin-1 beta (IL-1?) inhibitor Arcalyst (rilonacept) for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years and older.
Recurrent pericarditis is an autoinflammatory cardiovascular disease that often presents with chest pain, and is associated with changes in electrical conduction and build-up of fluid around the heart.
The FDA approval is based on positive data from the RHAPSODY trial in recurrent pericarditis. Data from this trial showed that Arcalyst treatment improved clinically meaningful outcomes associated with the significant unmet medical need in recurrent pericarditis.
There were rapid and sustained reductions in both reported pain and inflammation as early as after the first dose of Arcalyst.
“The approval of Arcalyst in recurrent pericarditis is an extremely important achievement for those suffering from this disease as there can be significant impact on a patient’s physical and emotional health as well as quality of life,” said Dona Winnowski, president of the Pericarditis Alliance.
“The development and commercialisation of new medicines for underserved and severe diseases are essential, and this first FDA-approved therapy in recurrent pericarditis brings hope to patients and their families,” she added.

Scott Pharma – 25.03.2025
SMI – 24/03/2025
Chemspec Europe – 27.02.2025
PHARMAP: Mon 14 October 2024, 10.36
FujiFilm Skyscraper: 26th November 2024
Woolcool 26 March 2024, 16:16
Biopharma group 6 March 2024, 09:40
EyeC 18 March 2024, 13:10
L.B. Bohle – 08.04.2025